NASDAQ : MRVI
Maravai LifeSciences Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.81 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.03B |
| Enterprise Value | 2.18B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 148.99M |
| Shares Outstanding | 259.67M |
| Shares Change (YoY) | +2.29% |
| Shares Change (QoQ) | +1.07% |
| Owned by Insiders (%) | 3.55% |
| Owned by Institutions (%) | 75.21% |
| Float | 106.40M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.71 |
| Forward PS | 9.51 |
| PB Ratio | 5.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 10.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.05 |
| Quick Ratio | 2.63 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 49.18 |
| Debt / FCF | n/a |
| Interest Coverage | -2.86 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -33.05% |
| Return on Assets (ROA) | -5.71% |
| Return on Invested Capital (ROIC) | -13.41% |
| Return on Capital Employed (ROCE) | -12.12% |
| Weighted Average Cost of Capital (WACC) | 7.38% |
| Revenue Per Employee | $503,072 |
| Profits Per Employee | -$186,472 |
| Employee Count | 415 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 3.05 |
Taxes
| Measure | Value |
|---|
| Income Tax | -408,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +154.40% |
| 50-Day Moving Average | 7.50 |
| 200-Day Moving Average | 5.24 |
| Relative Strength Index (RSI) | 53.56 |
| Average Volume (20 Days) | 2,502,502 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 13.35M |
| Short Previous Month | 13.83M |
| Short % of Shares Out | 5.14% |
| Short % of Float | 12.55% |
| Short Ratio (days to cover) | 4.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 208.78M |
| Gross Profit | 74.55M |
| Operating Income | -68.53M |
| Pretax Income | -136.49M |
| Net Income | -77.39M |
| EBITDA | -19.75M |
| EBIT | -68.53M |
| Loss Per Share | -$0.53 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 70.09M |
| Total Debt | 218.10M |
| Net Cash | -148.01M |
| Net Cash Per Share | -$0.57 |
| Equity (Book Value) | 355.59M |
| Book Value Per Share | 1.37 |
| Working Capital | 117.24M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.26M |
| Capital Expenditures | -10.58M |
| Depreciation & Amortization | 48.78M |
| Net Borrowing | -146.96M |
| Free Cash Flow | -35.84M |
| FCF Per Share | -$0.14 |
Margins
| Measure | Value |
|---|
| Gross Margin | 35.71% |
| Operating Margin | -32.82% |
| Pretax Margin | -65.38% |
| Profit Margin | -37.07% |
| EBITDA Margin | -9.46% |
| EBIT Margin | -32.82% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.29% |
| Shareholder Yield | -2.29% |
| Earnings Yield | -6.78% |
| FCF Yield | -1.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.50 |
| Price Target Difference | 8.84% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 9.47% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.39 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |